High blood pressure is a major risk factor for coronary heart disease and stroke^[@R4]^. Large genome-wide association studies in Europeans have reported 29 novel loci for systolic and diastolic blood pressure (SBP and DBP) where alleles have effect sizes of up to 0.5-1mm Hg^[@R1]-[@R3]^. Even small increments in blood pressure levels have important effects on cardiovascular morbidity and mortality at the population level^[@R5]^. We undertook a genome-wide association study of two further blood pressure phenotypes, pulse pressure (PP, the difference between SBP and DBP), a measure of stiffness of the main arteries, and mean arterial pressure (MAP), a weighted average of SBP and DBP. Both PP and MAP are predictive of hypertension^[@R6]^ and cardiovascular disease^[@R7]-[@R9]^.

This study was undertaken by the International Consortium of Blood Pressure Genome-Wide Association Studies (ICBP-GWAS) which aims to further the understanding of the genetic architecture underlying blood pressure. The initial publication by this consortium^[@R1]^ studied SBP and DBP with discovery GWAS among 69,395 people and a combined sample of \~200,000 Europeans. The two blood pressure phenotypes reported here, namely PP and MAP, were not previously analysed. All but one study that was included in the discovery GWAS of the study of SBP and DBP were included in the discovery GWAS stage of this study. In addition, a further 6 studies not included in the previous study^[@R1]^ were included here bringing our discovery GWAS sample size to 74,064.

We first conducted a genome-wide association meta-analysis of PP and MAP in 74,064 individuals of European ancestry from 35 studies ([Supplementary Table 1A](#SD2){ref-type="supplementary-material"}). Genotypes were imputed using HapMap. To account for effects of anti-hypertensive treatments, we imputed underlying SBP and DBP by adding a constant to each^[@R2],[@R3]^. Associations were adjusted for age, age^[@R2]^, sex and body mass index. We combined results across studies using an inverse variance weighted meta-analysis and, to correct for residual test statistic inflation, applied genomic control (GC) both to study-level association statistics and to the meta-analysis (λ~GC~=1.08 for PP, λ~GC~=1.12 for MAP)^[@R10]^. The QQ plots show an excess of extreme values largely accounted for by a modest number of genomic regions ([Supplementary Figures 1 (a) -- (b)](#SD2){ref-type="supplementary-material"}). Independent follow-up analyses were performed in 48,607 individuals of European ancestry ([Online Methods and Supplementary Note](#SD2){ref-type="supplementary-material"}).

SNPs in 12 regions showed genome-wide significant association (*P*\<5×10^-8^) with either PP or MAP in our discovery data (Stage 1) ([Supplementary Figures 1 (c) -- (d)](#SD2){ref-type="supplementary-material"}), including two novel regions for PP (7q22.3 near *PIK3CG, P*=1.2×10^-10^ and 11q24.3 near *ADAMTS8, P*=8.5×10^-11^; [Table 1](#T1){ref-type="table"}) and 10 regions previously associated with SBP and DBP ([Supplementary Table 2A for PP, Supplementary Table 2B for MAP](#SD2){ref-type="supplementary-material"})^[@R1]-[@R3]^. For follow-up in a series of independent cohorts we selected 99 SNPs comprising those with *P*\<1×10^-5^ for either PP or MAP and SNPs reported in recent large genome-wide association studies of SBP and DBP^[@R1]-[@R3]^ to evaluate their effects on PP and MAP (Stage 2: [Online Methods, Supplementary Note](#SD2){ref-type="supplementary-material"}).

After meta-analysis of the Stage 1 and Stage 2 data ([Supplementary Table 2C](#SD2){ref-type="supplementary-material"}), the two novel regions showing genome-wide association with PP after Stage 1 (near *PIK3CG* and near *ADAMTS8*) remained genome-wide significant. In addition, we found genome-wide significant associations for SNPs at two further novel loci for PP (at 4q12 near *CHIC2/PDGFRA* and 8q24.12 in *NOV*), two novel loci for MAP (3p21.31 in *MAP4*, 10q25.3 near *ADRB1*), and one locus for both traits (2q24.3 near *FIGN*) ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}) which has not previously shown an association with SBP or DBP in Europeans but which has recently been associated with SBP in east Asians (see [Supplementary Note](#SD2){ref-type="supplementary-material"})^[@R11]^. Forest plots of the Stage 1 effect sizes and standard errors are shown in [Supplementary Figure 2](#SD2){ref-type="supplementary-material"}. The novel signals for MAP were strongly associated with both SBP and DBP (*P*=7.7×10^-7^ to *P*=1.8×10^-12^), reflecting the high inter-correlations among these three blood pressure traits^[@R12],[@R13]^. For the sentinel SNPs in three of the novel PP loci, the estimated effects on SBP were in the opposite direction to the effects on DBP ([Table 1](#T1){ref-type="table"}, [Figure 2](#F2){ref-type="fig"}, [Supplementary Tables 2D and 2E](#SD2){ref-type="supplementary-material"}). Our findings show that analyses of PP and MAP reveal loci influencing blood pressure phenotypes which may not be detectable by studying SBP and DBP separately. Identification of novel genetic associations could help inform understanding about possible distinct mechanisms underlying relationships of PP with vascular risk^[@R14],[@R15]^.

Five additional loci for PP and 19 loci for MAP reaching genome-wide significance (*P*\<5×10^-8^, Stage 1 and Stage 2 combined) were recently shown to be associated with SBP/DBP^[@R1]-[@R3]^ ([Supplementary Tables 2A and 2B](#SD2){ref-type="supplementary-material"}). We used sentinel SNPs from both the novel and known regions showing genome-wide significant associations with PP or MAP in the combined Stage 1 and 2 data to create weighted risk scores for: i) PP (10 independent SNPs) and; ii) MAP (22 SNPs) ([Supplementary Table 2F](#SD2){ref-type="supplementary-material"}). We studied the associations of both risk scores with hypertension and blood pressure related outcomes including coronary heart disease, heart failure, stroke, echocardiographic measures of left ventricular structure, pulse wave velocity, renal function and renal failure. Adjusting for multiple testing for the 12 traits evaluated (*P*=0.05/12=4.1×10^-3^), the PP SNP risk score was associated with prevalent hypertension (*P*=7.9×10^-6^), incident stroke (*P*=4.9×10^-4^) and coronary heart disease (*P*=4.3×10^-4^), and the MAP SNP risk score was associated with hypertension (*P*=5.1×10^-16^), coronary heart disease (*P*=4.0 ×10^-20^), stroke (*P*=0.0019) and left ventricular wall thickness (*P*=2.1×10^-4^) ([Supplementary Table 3A](#SD2){ref-type="supplementary-material"}), confirming the clinical relevance of these measures of blood pressure phenotype^[@R8],[@R9]^. For a range of blood pressure related outcomes (see [Supplementary Note](#SD2){ref-type="supplementary-material"}), we compared *P* values for the PP risk score and a series of 1000 permutations of SBP risk scores, each based on 10 of the 26 blood pressure SNPs associated with SBP but not PP, constraining the selection of SNPs to have similar sized effects for SBP as those of the 10 PP SNPs. The PP risk score had a significantly (*P*\<0.05) greater association with risk of ischemic stroke than the SBP risk score ([Supplementary Note and Supplementary Table 3B](#SD2){ref-type="supplementary-material"}).

None of the genes in the identified novel regions is a strong candidate for blood pressure regulation, although several are implicated in mechanisms that may influence blood pressure. The most significant association with PP is within a putative mRNA clone (AF086203) spanning \~13.7kb at 7q22.3, 94kb upstream of *PIK3CG* (rs17477177, *P*=2.3×10^-13^, [Table 1](#T1){ref-type="table"} and [Figure 1a](#F1){ref-type="fig"}). *PIK3CG* encodes the phosphoinositide-3-kinase, catalytic, gamma polypeptide protein which phosphorylates phosphoinositides and modulates extracellular signals. This region was earlier associated with mean platelet volume, platelet count, and platelet aggregation^[@R16]-[@R18]^, but the sentinel SNPs reported in those studies are independent of SNP rs17477177 reported here (r^2^\<0.01). Mice lacking the catalytic subunit of PI3Kγ have shown resistance to SBP-lowering effects of beta-adrenergic receptor agonists^[@R19]^; PI3Kγ activity is increased in the failing human heart and associated with down-regulation of beta-adrenergic receptors in the plasma membrane^[@R20]^. The second locus for PP located at 11q24.3 spans 35.5kb with the top-ranking SNP (rs11222084, *P*=1.9×10^-11^, [Figure 1b](#F1){ref-type="fig"}) lying 1.6kb downstream of *ADAMTS-8*. This gene is highly expressed in macrophage-rich areas of human atherosclerotic plaques and may affect extracellular matrix remodeling^[@R21]^. The third locus for PP spans 28.5kb at 8q24.12 with the sentinel SNP (rs2071518, *P*=3.7×10^-9^, [Figure 1c](#F1){ref-type="fig"}) located in the 3'UTR of *NOV* which encodes the nephroblastoma overexpressed (CCN3) protein, associated with angiogenesis, proliferation, and inhibition of vascular smooth muscle cell growth and migration^[@R22]^, and with reduced neointimal thickening in mice null for CCN3^[@R23]^. Mice with mutations in *NOV* that truncate the NOV protein exhibit abnormal cardiac development^[@R24]^. Of the genes evaluated for expression in human aortic samples at the novel PP loci, *NOV* showed by far the highest expression levels ([Supplementary Note and Supplementary Figure 3](#SD2){ref-type="supplementary-material"}). The fourth locus for PP is 4q12 with the top-ranking SNP (rs871606, *P*=1.3×10^-8^, [Figure 1d](#F1){ref-type="fig"}) located 76.7kb downstream of *CHIC2* which encodes a cysteine-rich hydrophobic domain containing protein associated with acute myeloid leukaemia^[@R25]^. This SNP is located 296kb upstream of *PDGFRA* which encodes platelet-derived growth factor receptor alpha, a cell surface receptor for members of the platelet-derived growth factor family involved in kidney development. Variants in *PDGFRA* have been associated with red blood cell count and other haematological indices^[@R26]^ but are independent (r^2^\<0.3) of rs871606.

For MAP we identified two novel loci. The first locus for MAP is at 10q25.3, 22.3kb upstream of *ADRB1* (rs2782980, *P*=2.5×10^-9^, [Figure 1e](#F1){ref-type="fig"}). *ADRB1* encodes the beta-1-adrenergic receptor, which mediates the effects of the stimulatory G protein and cAMP/protein kinase A pathway to increase heart rate and myocardial contraction. Polymorphisms in this gene have been associated with resting heart rate, response to beta-blockers^[@R27]^, and hypertension^[@R28]^. *ADRB1* knockout mice have no difference in heart rate or blood pressure compared with the wild type but do exhibit a significant reduction in the response of both phenotypes to catecholamines^[@R29]^. SNP rs2782980 is associated with expression of an *ADRB1* transcript in brain tissue ([Supplementary Note and Supplementary Figure 4A](#SD2){ref-type="supplementary-material"}). The second locus for MAP spans over 300kb at 3p21.31 with the top-ranking SNP (rs319690, *P*=2.7×10^-8^, [Figure 1f](#F1){ref-type="fig"}) lying within an intron of the microtubule associated protein 4 gene, *MAP4*. Coating of microtubules by MAP4 may inhibit beta adrenergic receptor recycling and number, as seen in cardiac hypertrophy and failure^[@R30]^. *MAP4* was detectably expressed in human aortic samples ([Supplementary Note and Supplementary Figure 3](#SD2){ref-type="supplementary-material"}).

The locus associated both with PP (SNP rs13002573, *P*=1.8×10^-8^, [Figure 1g](#F1){ref-type="fig"}) and MAP (rs1446468, *P*= 6.5×10^-12^, [Figure 1h](#F1){ref-type="fig"}) is in an intergenic region spanning \~280kb at 2q24.3. Although the two signals are \~50kb apart and statistically independent (r^2^=0.075), rs13002573 is highly correlated (r^2^=1 in HapMap CEU population, r^2^=0.87 in HapMap JPT+CHB) with rs16849225 which has recently been reported as showing association with SBP in a GWAS of 19,608 subjects of east Asian origin with follow-up in a further 30,765 individuals (combined result: *P*=3.5×10^-11^) ^[@R11]^ (see [Supplementary Note](#SD2){ref-type="supplementary-material"}). In our combined dataset in 116,998 Europeans, the association *P* value for rs13002573 with SBP was *P*=3.25×10^-7^. The top PP SNP lies \~320kb upstream of *FIGN* and \~430kb downstream of *GRB14* (growth factor receptor-bound protein 14). Relatively little is known regarding *FIGN* (fidgetin).

We report six novel loci associated with PP and MAP based on genome-wide discovery and follow-up in over \~120,000 individuals, and a further locus (near *FIGN*) not previously reported in Europeans. Our results expand knowledge of the genetic architecture of blood pressure and PP regulation and may give clues as to possible novel targets for blood pressure therapies.

Online Methods {#S1}
==============

Pulse pressure was defined as systolic minus diastolic pressure and MAP as 2/3 diastolic plus 1/3 systolic pressure. A two-staged analysis was used to discover genes associated with PP and MAP.

Stage 1 samples and analyses {#S2}
----------------------------

Stage 1 was a meta-analysis of directly genotyped and imputed SNPs from population-based or control samples from case-control studies, in the International Consortium of Blood Pressure Genome-wide Association Studies (ICBP-GWAS). The characteristics of the 35 studies, including demographics, genotyping arrays, quality control filters and statistical analysis methods used are listed in [Supplementary Tables 1A and 1B](#SD2){ref-type="supplementary-material"}. Imputation of allele dosage of ungenotyped SNPs in HapMap CEU v21a or v22 was carried out by each of the studies using MACH^[@R31]^, IMPUTE^[@R32]^ or BIMBAM^[@R33]^ with parameters and pre-imputation filters as specified in [Supplementary Table 1B](#SD2){ref-type="supplementary-material"}. SNPs were excluded from analysis if the study-specific imputation quality (r2.hat in MACH or .info in IMPUTE) was \<0.3. In total, up to 2652054 genotyped or imputed autosomal SNPs were analyzed. Full details of the models, methods, and corrections for antihypertensive treatment are provided in the [Supplementary methods](#SD2){ref-type="supplementary-material"}. All analyses assumed an additive genetic model and were adjusted for sex, age, age^[@R2]^, body mass index and ancestry principal components. In related individuals, regression methods that account for relatedness were applied. All study-specific effect estimates and coded alleles were oriented to the forward strand of the HapMap release 22 with the alphabetically higher allele as the coded allele. To capture loss of power due to imperfect imputation, we estimated "N effective" as the sum of the study-specific products of the imputation quality metric and the sample size. No filtering on minor allele frequency was done. Genomic control was carried out on study-level data and inverse variance weighting was used for meta-analysis of Stage 1. The meta-analysis results were subject to genomic control. Lambda estimates are given in [Supplementary Table 1A](#SD2){ref-type="supplementary-material"}.

Selection of SNPs for Stage 2 {#S3}
-----------------------------

We aimed in Stage 2 to follow up SNPs which had evidence of association with PP or MAP and, for completeness, to evaluate the effects on PP and MAP of SNPs reported in recent large genome-wide association studies of SBP and DBP^[@R1]-[@R3]^. All SNPs with *P*\<1×10^-5^ for association with either PP or MAP (or both) were divided into independent regions based on LD and the most significant SNP was selected from each region. Within the *FIGN* region, different SNPs were associated with PP and with MAP and both SNPs were followed up in Stage 2. For SNPs with an N effective \<75% of total N, a proxy was also included if it had *P* \<1×10^-5^ and an r^2^\>0.6 with the top SNP (this occurred for one SNP). For all regions that had previously shown association with SBP or DBP^[@R1]-[@R3]^, the sentinel SNP for PP and MAP and the previously reported SNP for SBP and DBP were followed up. In all, 99 SNPs were followed up in Stage 2 ([Supplementary Note](#SD2){ref-type="supplementary-material"}), comprising: 44 SNPs from 22 loci with PP or MAP associations (*P*\<1×10^-5^) in Stage 1 data and with previously reported SBP or DBP associations; 47 SNPs from 45 loci with PP or MAP associations (*P*\<1×10^-5^) in Stage 1 data only and; 8 SNPs from 7 loci with previously reported SBP or DBP associations and no association (*P*\<1×10^-5^) with PP or MAP in the Stage 1 data.

Stage 2 {#S4}
-------

The characteristics of the Stage 2 studies, including the genotyping and imputation approaches, are described in [Supplementary Tables 1A and 1B](#SD2){ref-type="supplementary-material"} and the details of corrections for treatment described in the [Supplementary Note](#SD2){ref-type="supplementary-material"}. For the 99 SNPs selected for follow-up, the Stage 2 studies followed the analysis approach adopted in the Stage 1 analyses. Meta-analysis was done using the inverse variance weights method.

Pooled analysis of first and second stage samples {#S5}
-------------------------------------------------

Meta-analysis from stages 1 and 2 was conducted using inverse variance weighting and genomic control applied. A threshold of 5×10^-8^ was taken for genome-wide significance.

Calculation of risk scores {#S6}
--------------------------

We calculated risk scores based on the most significantly associated SNP from all regions which were genome-wide significant after meta-analysis of Stages 1 and 2 for i) PP (10 SNPs) and ii) MAP (22 SNPs) ([Supplementary Table 2F](#SD2){ref-type="supplementary-material"}). Each risk score was constructed using an approach described in the [Supplementary Note](#SD2){ref-type="supplementary-material"} and was tested for association with hypertension, coronary artery disease, stroke, hypertension, chronic kidney disease, heart failure, microalbuminuria, and with continuous traits left ventricular mass, left ventricular wall thickness, pulse wave velocity, serum creatinine, eGFR and urinary albumin:creatinine ratio ([Supplementary Table 3](#SD2){ref-type="supplementary-material"}).

Additional analyses {#S7}
-------------------

Identification of potentially functional SNPs in LD with the reported sentinel SNPs, eQTL analyses and expression analyses in human aortic samples were also carried out as discussed in the [Supplementary Note and Supplementary Figures 3 and 4](#SD2){ref-type="supplementary-material"}.

Supplementary Material {#S8}
======================

A number of the participating studies and authors are members of the CHARGE and Global BPgen consortia. Many funding mechanisms by NIH/NHLBI, European, and private funding agencies contributed to this work and a full list is provided in the [Supplementary Note](#SD2){ref-type="supplementary-material"}.
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###### 

Regional association plots of the 8 SNPs at 7 loci showing genome-wide significant association (*P*\<5×10^-8^) with pulse pressure and/or mean arterial pressure. Statistical significance of each SNP shown on the --log~10~ scale as a function of chromosome position (NCBI build 36) in the meta-analysis of stage 1 only. The sentinel SNP at each locus is shown in blue; the correlations (r^2^) of each of the surrounding SNPs to the sentinel SNP are shown in the colours indicated in the key. Fine --scale recombination rate is shown in blue. Gene positions are indicated at the bottom.
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![Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) effect sizes (beta coefficients) for all BP SNPs identified in the present study and Ehret et al.^[@R1]^, obtained from follow-up samples only. Beta coefficients are shown as standard deviation (s.d.) differences so that SBP and DBP are measured on comparable scales. Points are colour-coded according to whether they are genome-wide significant (*P*\<5×10^-8^) for Pulse Pressure (PP) (red), Mean Arterial Pressure (MAP) (blue) or both PP and MAP (purple) in stages 1 and 2 of the present study, while those that are significant only for SBP and/or DBP from Ehret et al.^[@R1]^ are shown in black. The novel SNPs found in the present study are labelled with their rs-numbers. For illustration purposes the effect allele for each SNP is defined such that the direction of the SBP effect is always positive.](nihms316759f2){#F2}

###### 

Summary of Pulse Pressure (PP) and Mean Arterial Pressure (MAP) association results from Stages 1 and 2 and the combined analysis for all SNPs that showed genome-wide significant (*P*\<5×10^-8^) association with PP and/or MAP on combined analysis and which had not previously been reported for Systolic (SBP) or Diastolic Blood Pressure (DBP). SBP and DBP combined Stage 1 and Stage 2 association results, based on the same sample set as for PP and MAP are also shown (full SBP and DBP results are in [Supplementary Tables 2D and 2E](#SD2){ref-type="supplementary-material"}). Genome-wide significant associations (*P*\<5×10^-8^) are shown in bold.

  Locus                                         Coded allele & freq   Stage 1   Stage 2          Stage 1+ 2         SBP Stage 1+2   DBP Stage 1+2                                                                                                                    
  --------------------------------------------- --------------------- --------- ---------------- ------------------ --------------- ---------------- ------------- -------- ---------------- ------------------ ---------------- ------------------ ---------------- -----------------
  **Pulse Pressure**                                                                                                                                                                                                                                                 
  rs13002573 near *FIGN* chr2: 164623454        G 0.203               73043     -0.320 (0.07)    5.43×10^-6^        43955           -0.296 (0.089)   8.58×10^-4^   116998   -0.310 (0.055)   **1.76×10^-8^**    -0.416 (0.081)   3.25×10^-7^        -0.107 (0.052)   4.02×20^-2^
  rs871606 near *CHIC2* chr4: 54494002          T 0.85                71444     0.428 (0.096)    9.28×10^-06^       44082           0.431 (0.121)    3.75×10^-4^   115525   0.429 (0.075)    **1.32×10^-8^**    0.403 (0.112)    3.04×10^-4^        -0.010 (0.072)   8.85×10^-1^
  rs17477177 near *PIK3CG* chr7: 106199094      T 0.717               72997     -0.460 (0.071)   **1.19×10^-10^**   39999           -0.344 (0.094)   2.72×10^-4^   112996   -0.418 (0.057)   **2.27×10^-13^**   -0.552 (0.084)   **5.67×10^-11^**   -0.081 (0.055)   1.40×10^-1^
  rs2071518 *NOV* (3' UTR) chr8: 120504993      T 0.167               73252     0.304 (0.067)    5.72×10^-6^        45804           0.323 (0.086)    1.60×10^-4^   119056   0.312 (0.053)    **3.66×10^-9^**    0.181 (0.078)    2.08×10^-2^        -0.145 (0.050)   3.89×10^-3^
  rs11222084 near *ADAMTS-8* chr11: 129778440   T 0.375               67704     0.415 (0.064)    **8.45×10^-11^**   40391           0.211 (0.081)    9.17×10^-3^   108095   0.337 (0.05)     **1.90×10^-11^**   0.263 (.074)     4.00×10^-4^        -0.101 (0.048)   3.44×10^-2^
  **Mean Arterial Pressure**                                                                                                                                                                                                                                         
  rs1446468 near *FIGN* chr2: 164671732         T 0.534               69264     -0.291 (0.061)   1.68×10^-6^        39650           -0.418 (0.082)   3.80×10^-7^   108914   -0.336 (0.049)   **6.46×10^-12^**   -0.499 (0.071)   **1.82×10^-12^**   -0.265 (0.046)   **6.88×10^-9^**
  rs319690 *MAP4* (intron) chr3: 47902488       T 0.51                59137     0.306 (0.066)    3.88×10^-6^        34359           0.280 (0.09)     1.89×10^-3^   93496    0.297 (0.053)    **2.69×10^-8^**    0.423 (0.077)    **4.74×10^-8^**    0.282 (0.05)     **1.84×10^-8^**
  rs2782980 near *ADRB1* chr10: 115771517       T 0.198               61284     -0.345 (0.071)   1.14×10^-6^        37788           -0.326 (0.094)   5.55×10^-4^   99072    -0.338 (0.057)   **2.46×10^-9^**    -0.406 (0.082)   7.66×10^-7^        -0.283 (0.053)   9.60×10^-8^

[^1]: A list of consortium members is supplied in the Supplementary Note.

[^2]: These authors contributed equally.
